This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Women's Triple-Negative First-Line Study: A Phase ...
Clinical trial

Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy

Read time: 1 mins
Last updated:1st Apr 2016

The goal of this clinical research study is to learn if receiving 4 cycles of an experimental chemotherapy combination before surgery can help to shrink or slow the growth of tumors before they are removed through surgery. The safety of this combination will also be studied.


Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Estimated Enrollment: 37
Study Start Date: April 2016
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Panitumumab + Carboplatin + Paclitaxel

Category Value
Study start date 2016-04-01

View full details